1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Merck gets BACE boost in Alzheimer's race

 
• By Eleanor Malone

Merck & Co's MK-8931 has successfully cleared an early hurdle in the race to find a product that might treat Alzheimer's disease through beta secretase enzyme (BACE) inhibition. The firm reported positive Phase Ib results showing a quick, dose-dependent reduction in amyloid.

Merck & Co's MK-8931 has successfully cleared an early hurdle in the race to find a product that might treat Alzheimer's disease through beta secretase enzyme (BACE) inhibition. The firm reported positive Phase Ib results showing a quick, dose-dependent reduction in amyloid.

The absence of liver abnormalities was also reassuring, given that this issue forced Lilly to halt a Phase II trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?